NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyImproved Drug Susceptibility Testing (DST) for Mycobacteria
About This Grant
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Grant Summary
Improved Drug Susceptibility Testing (DST) for Mycobacteria is a National Institutes of Health grant providing funding that varies by award for tribal government, municipality, nonprofit. This is a forecast: it is not yet open for applications, and the estimated deadline is 2027-05-28. Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 800+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
- Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
How to Apply
Not stated by funder
Estimated 2027-05-28
- 1Confirm your organization is eligible for Improved Drug Susceptibility Testing (DST) for Mycobacteria from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Improved Drug Susceptibility Testing (DST) for Mycobacteria: Frequently Asked Questions
Who is eligible for the Improved Drug Susceptibility Testing (DST) for Mycobacteria?
Improved Drug Susceptibility Testing (DST) for Mycobacteria is offered by National Institutes of Health. The listing names these applicant types: tribal government, municipality, nonprofit, university, small business, school district. It is open to organizations nationwide unless the funder specifies otherwise. The funder's eligibility section is the authority, so confirm your organization type, location, and the population or project served against it before applying.
How much funding does the Improved Drug Susceptibility Testing (DST) for Mycobacteria provide?
National Institutes of Health does not publish a set award amount for Improved Drug Susceptibility Testing (DST) for Mycobacteria, so award sizes vary. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs, and confirm the expected range with the funder.
When is the Improved Drug Susceptibility Testing (DST) for Mycobacteria deadline?
Improved Drug Susceptibility Testing (DST) for Mycobacteria is a forecast from National Institutes of Health: it is not yet open for applications. The funder's estimated deadline is 2027-05-28, and forecast dates often change. Confirm the official posting with the funder before you prepare an application.
How do you apply for the Improved Drug Susceptibility Testing (DST) for Mycobacteria?
To apply for Improved Drug Susceptibility Testing (DST) for Mycobacteria, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.
Browse More Grants
Related Grants
State Veterans Home Construction Grant Program
Construction of State Home Facilities — up to $275M
Advancing Global Health
Bureau of Global Health Security and Diplomacy — up to $250M
Title X Family Planning Services Grants
Office of the Assistant Secretary for Health — up to $22M
Fiscal Year (FY) 2027 Service Area Competition (SAC)
Health Resources and Services Administration — up to $10.1M
Occupational Safety and Health Education and Research Centers (T42)
Centers for Disease Control and Prevention - ERA — up to $9M
BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed)
National Institutes of Health — up to $8M